If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, ______†______ and how. 10.ǂ MODIFICATIONS see below at page 11 If the intervention was modified during the course of the describe the changes (what, why, when, ______†______ and how). HOW WELL 11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any see below at page 11 _____________ strategies were used to maintain or improve fidelity, describe them. If intervention adherence or fidelity was assessed, describe the extent to which the intervention see at page 11 _____________ 12.ǂ Actual: was delivered as planned. ** Authors - use N/A if an item is not applicable for the intervention being described. Reviewers use if information about the element is not reported/not sufficiently – ‘?’ reported. If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other † published papers (provide citation details) or a website (provide the URL). If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. ǂ * This checklist has been used in conjunction with the TIDieR guide (see 2014;348:g1687) which contains an explanation and elaboration for each item. BMJ * The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a is being reported, the randomised TIDieR checklist should be used in conjunction with the CONSORT statement (see ) as an extension of Item 5 of the CONSORT 2010 Statement. When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 Statement (see ). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see ).
If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how. ______†______ 10.ǂ MODIFICATIONS see below at page 11 If the intervention was modified during the course of the describe the changes (what, why, when, and how). ______†______ HOW WELL 11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them. see below at page 11 _____________ 12.ǂ Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned. see at page 11 _____________ ** Authors - use N/A if an item is not applicable for the intervention being described. Reviewers – use ‘?’ if information about the element is not reported/not sufficiently reported. † If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL). ǂ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. * This checklist has been used in conjunction with the TIDieR guide (see BMJ 2014;348:g1687) which contains an explanation and elaboration for each item. * The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a randomised is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see ) as an extension of Item 5 of the CONSORT 2010 Statement. When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 Statement (see ). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see ).
1-s2.0-S0149718918300090-mmc1.docx